Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia

Acta Haematol. 2011;126(2):119-21. doi: 10.1159/000328039. Epub 2011 Jun 10.

Abstract

We present 2 patients with hyperferritinemia, increased liver iron and hemochromatosis-associated HFE genotypes. At diagnosis, both patients had chronic anemia that prevented initiation of phlebotomy. Iron chelation with deferasirox proved to be a safe and effective means of substantially lowering ferritin levels.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Benzoates / therapeutic use*
  • Chelation Therapy*
  • Deferasirox
  • Female
  • Genotype
  • Hemochromatosis / drug therapy*
  • Hemochromatosis Protein
  • Histocompatibility Antigens Class I / genetics*
  • Humans
  • Iron Chelating Agents / therapeutic use*
  • Male
  • Membrane Proteins / genetics*
  • Treatment Outcome
  • Triazoles / therapeutic use*

Substances

  • Benzoates
  • HFE protein, human
  • Hemochromatosis Protein
  • Histocompatibility Antigens Class I
  • Iron Chelating Agents
  • Membrane Proteins
  • Triazoles
  • Deferasirox